Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features

Cancer

Volumn 110, Issue 3, 2007, Pages 551-555

  Dattoli, Michael ^a,f   Wallner, Kent ^b,c,d   True, Lawrence ^e   Cash, Jennifer ^a   Sorace, Richard ^a  

^a Brachytherapy Research Institute   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Dattoli Cancer Center   (United States)

Author keywords

Brachytherapy; Pd 103; Prostatic carcinoma

Indexed keywords

PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER INVASION; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; EXTRACAPSULAR CANCER EXTENSION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, HIGH-ENERGY; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547111263     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22810     Document Type: Article

References (21)

1. Blasko JC, Ragde H, Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocurie/Hypertherm Oncol. 1987;3:131-139.
2. Cooperberg M, Lubeck D, Meng M, Mehta S, Carroll P. The changing face of low-risk prostate cancer: trends in clinical prsentation and primary management. J Clin Oncol. 2004;22:2141-2149.
3. Hakenberg O, Wirth M, Hermann T, et al. Recommendations for the treatment of localized prostate cancer by permanent interstitial brachytherapy. Urol Int. 2002;70:15-20.
4. Pisansky T, Blute M, Hillman D, et al. The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer. 2002;95:513-519.
5. Khan MA, Partin AW. Partin tables: past and present. BJU Int. 2003;92:7-11.
6. Febles C, Valicenti R. Combining external beam radiotherapy with prostate brachytherapy: issues and rationale. Urology. 2004;64:855-861.
7. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
8. Brachman DG, Thomas T, Hilbe J, Beyer DC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys. 2000;48:111-117.
9. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839-850.
10. Merrick G, Butler W, Wallner K, Galbreath R, Adamovich E. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA <20 ng/ml. Am J Clin Oncol. 2004;27:611-615.
11. Merrick G, Butler W, Lief JH, Galbreath RW, Adamovich E. Biochemical outcome for hormone-naive intermediate-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation. Brachytherapy. 2002;1:95-101.
12. Stock RG, Cahlon O, Cesaretti J, Kollmeier M, Stone NN. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:1352-1359.
13. Dattoli MJ, Wallner KE, True L, Cash JC, Sorace RA. Prognostic Role of serum prostatic acid phosphatase for Pd-103 based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys. 1999;45:853-856.
14. Roy AV, Brower ME, Hayden JE. Sodium thymolphthalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem. 1998;17:1093-1102.
15. Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:1487-1493.
16. Denham JW, Steigler A, Lamb D, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet. 2005;6: 841-850.
17. D'Amico AV, Manola J, Loffredo M, Renshaw AA, Della-Croce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;293:821-827.
18. Davis BJ, Pisansky TM, Wilson TM, et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer. 1999;85:2630-2637.
19. Butzbach D, Waterman FM, Dicker AP. Can extraprostatic extension be treated by prostate brachytherapy? An analysis based on postimplant dosimetry. Int J Radiat Oncol Biol Phys. 2001;51:1196-1199.
20. Merrick GS, Butler WM, Wallner KE, Burden LR, Dougherty JE. Extracapsular dose distribution following permanent prostate brachytherapy. Am J Clin Oncol. 2003;26:178-189.
21. Critz F. Summary of simultaneous irradiation for prostate cancer. Urology. 2004;64:633-636.